Imaging Biometrics (LSE:IBAI) said its US subsidiary, Imaging Biometrics, has signed an annual subscription agreement with a major academic medical centre in the Midwest United States for IB Clinic, its automated brain tumour imaging software.
The London-listed company develops software used to measure and assess brain tumours, with products cleared by the US Food and Drug Administration and distributed worldwide through GE HealthCare and other partners.
The agreement is a renewable annual subscription on terms consistent with IB's other client contracts, with revenue recognised across the term and a full year's contribution expected in 2027.
IB Clinic automates the production of quantitative maps that help clinicians distinguish tumour tissue from treatment-related changes, a task traditionally requiring manual post-processing that can delay results and vary between operators.
The centre has also adopted a scanning method enabled by IB's software that halves the quantity of contrast agent injected into patients, an approach supported by peer-reviewed studies at both magnet strengths in common hospital use.
Trevor Brown, chief executive of Imaging Biometrics, said IB Clinic is "the platform through which our technology reaches routine hospital practice at scale."
Brown added that discussions continue with other medical centres considering subscriptions, with updates to follow "as and when they conclude."
News Intelligence what this means for the company
Imaging Biometrics has signed a renewable annual subscription agreement with a major US Midwest academic medical centre for IB Clinic, its automated brain tumour imaging software, with full-year revenue contribution expected in 2027. The deal adds recurring revenue but is not yet material to 2026 results; the company notes discussions with other centres are ongoing.
This represents validation of IB Clinic's commercial model in routine hospital practice and extends the company's recurring revenue base, but the timing of revenue recognition (2027 onwards) and the absence of deal size or customer count context limit near-term impact on the investment thesis.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
